Carregant...
Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery
With the recent FDA approval of the first siRNA-derived therapeutic, RNA interference (RNAi)-mediated gene therapy is undergoing a transition from research to the clinical space. The primary obstacle to realization of RNAi therapy has been the delivery of oligonucleotide payloads. This review aims t...
Guardat en:
| Publicat a: | Adv Mater |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6891135/ https://ncbi.nlm.nih.gov/pubmed/31566258 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/adma.201903637 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|